MedTrace Logo

Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

NCT01531712 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-08-29

No results posted yet for this study

Summary

Phase II study of neoadjuvant treatment with Gemcitabine, Tarceva and Oxaliplatin followed by chemotherapy with Tarceva and Gemcitabine in patients with pancreatic adenocarcinoma with borderline resectability. The primary objective is to determine the resectability rate of patients with pancreas adenocarcinoma with borderline resectability determined radiologically, treated with Gemcitabine, Tarceva and Oxaliplatin followed by radiotherapy with Gemcitabine and Tarceva.

Conditions

Interventions

DRUG

Gemcitabine

1000mg/m2 / / 40mg/m2

RADIATION

Radiotherapy

50.4 Gy

DRUG

Tarceva

100mg/day

DRUG

Oxaliplatin

100mg/m2 (only in QT)

Sponsors & Collaborators

  • Institut Català d'Oncologia

    lead OTHER

Principal Investigators

  • Berta Laquente, MD · ICO

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-10
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01531712 on ClinicalTrials.gov